$CRMNeutralMed

DA Davidson Cuts PT on Salesforce, Inc. (CRM) Following Q1 Results

DA Davidson cut its Salesforce (CRM) price target to $175 from $200 on May 28, keeping a Neutral rating, after the firm said Salesforce’s fiscal Q1 results and updated guidance did not strengthen confidence in FY27 top-line acceleration. On the same day, BMO Capital reduced its target to $215 from $225 and kept an Outperform rating, citing limited changes to FY27 growth expectations.

8/10
6/10
Med
Neutral
post-Q1 analyst target cuts (published pre-market/early session)
Neutral-to-cautious; target reductions reinforce a “not enough to re-rate” narrative

Street expectations appear to be staying muted despite a “strong start,” with multiple firms trimming targets and signaling limited change to FY27 top-line growth.

DA Davidson cut Salesforce’s price target to $175 from $200 and kept Neutral after fiscal Q1 results and updated FY27 guide disappointed bulls.

Near-term upside may be capped; expect choppy trading around analyst-target revisions rather than a decisive catalyst.

Background

The piece summarizes two analyst actions (DA Davidson and BMO) following Salesforce’s fiscal Q1 results and updated guidance.

Why it matters

Target cuts and maintained ratings suggest the market may not receive a fresh re-rating catalyst from Q1/guidance alone; focus shifts to whether subsequent quarters prove top-line acceleration.

Market relevance

Material for CRM positioning because it reflects sell-side sentiment shifts immediately after Q1, potentially influencing near-term flows and options positioning.

Market effects

Signals continued skepticism toward enterprise cloud/CRM growth re-acceleration narratives until FY27 top-line evidence improves.

Primarily US large-cap software sentiment; limited direct regional spillover implied.

Global enterprise software investors may treat this as another datapoint that Q1 results/guidance are not yet re-rating catalysts.

Alternative perspectives

If bulls believe the updated guide still supports acceleration later in FY27, the target cuts may be an overreaction to near-term expectations rather than a fundamental deterioration.

The article emphasizes “limited changes” to FY27 top-line expectations; traders may want to check whether consensus estimates moved materially after the Q1 release, not just analyst targets.

Key entities

  • Salesforce, Inc.

    Subject of the article; analyst price-target cuts after fiscal Q1 results and FY27 guidance interpretation.

  • DA Davidson

    Cut CRM price target to $175 from $200; maintained Neutral citing insufficient ammunition for bulls.

  • BMO Capital

    Cut CRM price target to $215 from $225; maintained Outperform, citing limited change to FY27 top-line growth expectations.

Related articles

$CRMMedAI 8/10

Salesforce (CRM) to Acquire Metering Platform M3ter to Enhance Agentforce Revenue Management

Salesforce (NYSE:CRM) said June 8 it signed a definitive agreement to acquire m3ter, a metering and rating platform for consumption-based monetization. Salesforce plans to integrate m3ter’s high-volume usage data ingestion into its Agentforce Revenue Management to help enterprises implement and automate flexible usage-based billing. The deal is expected to close in Q2 FY2027, subject to standard conditions.

$KLACMed

Stocks Supported by a Rebound in Chipmakers and AI Stocks

Markets were mixed overseas as investors weighed Fed and ECB policy expectations. US 10-year yields fell to 4.523% after weekly jobless claims rose and May producer prices rose less than expected. The ECB raised its deposit rate 25 bp to 2.25% and cut 2026 GDP to 0.8%. Chip and AI stocks rose on Oracle’s higher-than-expected capex; Oracle fell over its $70B full-year capex forecast. Navan lifted guidance to $907M-$913M; Voyager gained on BTIG’s $55 target.

$ADBEMedAI 8/10

Adobe Tumbles 9% on CFO Exit, Downgrades: Is the AI Threat Now Salesforce’s Problem Too?

Adobe shares fell about 9% to $198 after the company reported a beat-and-raise quarter but investors sold the news. Adobe posted record revenue of $6.62 billion (+13% YoY), non-GAAP EPS of $5.96, and operating cash flow of $2.17 billion, and it raised full-year guidance. The drop followed news that CFO Dan Durn will leave June 15 and analysts issued downgrades tied to leadership changes and concerns about AI and a freemium shift.

$CVSLow

CVS Health To Deliver Faster, More Personalized Call Center Care for Millions of Members With Salesforce's Agentforce Health

Salesforce (NYSE:CRM) and CVS Health (NYSE:CVS) said they expanded their collaboration using Salesforce’s Agentforce Health to improve call center interactions for CVS Health’s Aetna and CVS Caremark businesses. The platform will use AI agents and secure data access to help resolve member and provider inquiries faster, supporting about 185 million people served annually and 1.5 million providers.

$INTCMed

US stocks: Wall Street ticks up as chips rebound, Middle East in focus

US stocks rose Thursday as chipmakers rebounded after a prior selloff pushed tech into correction territory. Intel gained 10%, while Nvidia and Micron rose 1.3% and 2.4%; the S&P 500 tech index climbed 1.4% and Philadelphia Semis rose 4.5%. Oracle fell 12.5% on higher-than-expected fiscal 2027 capex guidance. Investors also weighed Middle East developments and US producer prices.

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.